Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

U.S. calls for 'transparent' new investigation into COVID origins

Published 05/25/2021, 05:54 AM
Updated 05/25/2021, 07:29 PM
© Reuters. FILE PHOTO: Xavier Becerra, nominee for Secretary of Health and Human Services, answers questions during his Senate Finance Committee nomination hearing on Capitol Hill in Washington, DC, U.S., February 24, 2021. Greg Nash/Pool via REUTERS/File Photo

By Stephanie Nebehay

GENEVA (Reuters) - The United States called on Tuesday for international experts to be allowed to evaluate the source of the coronavirus and the "early days of the outbreak" in a second phase of an investigation into the origins of the coronavirus.

U.S. intelligence agencies are examining reports that researchers at a Chinese virology laboratory were seriously ill in 2019 a month before the first cases of COVID-19 were reported, according to U.S. government sources who cautioned on Monday that there is still no proof the disease originated at the lab.

"Phase 2 of the COVID origins study must be launched with terms of reference that are transparent, science-based, and give international experts the independence to fully assess the source of the virus and the early days of the outbreak," U.S. health secretary Xavier Becerra said in a video message to the annual ministerial meeting of the World Health Organization.

Becerra did not mention China directly, where the first known human cases of COVID-19 emerged in the central city of Wuhan in December 2019.

The origin of the virus is hotly contested. In a report https://www.who.int/health-topics/coronavirus/origins-of-the-virus issued in March written jointly with Chinese scientists, a WHO-led team that spent four weeks in and around Wuhan in January and February said the virus had probably been transmitted from bats to humans through another animal, and that "introduction through a laboratory incident was considered to be an extremely unlikely pathway".

A WHO spokesman, Tarik Jasarevic, asking about a follow-up mission, told Reuters on Monday that the agency was reviewing the recommendations from the report at the technical level.

© Reuters. FILE PHOTO: Xavier Becerra, nominee for Secretary of Health and Human Services, answers questions during his Senate Finance Committee nomination hearing on Capitol Hill in Washington, DC, U.S., February 24, 2021. Greg Nash/Pool via REUTERS/File Photo

"The technical teams will prepare a proposal for the next studies that will need to be carried out, and will present that to the Director-General for his consideration," he said, referring to WHO director-general Tedros Adhanom Ghebreyesus.

Jasarevic, noting Tedros' remarks on March 30, said that further studies would be needed in a range of areas, including on the early detection of cases and clusters, the potential roles of animal markets, transmission via the food chain and the laboratory incident hypothesis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.